Bio-Rad Laboratories Q2 2024 Adj. EPS $3.11 Beats $2.01 Estimate, Sales $638.5M Miss $645.789M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Rad Laboratories (NYSE:BIO) reported Q2 2024 adjusted EPS of $3.11, beating the $2.01 estimate by 54.73%. However, sales of $638.5M missed the $645.789M estimate by 1.13%, marking a 6.25% decrease from the same period last year.
August 01, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Rad Laboratories reported Q2 2024 adjusted EPS of $3.11, significantly beating the $2.01 estimate. However, sales of $638.5M missed the $645.789M estimate and decreased by 6.25% YoY.
The significant beat on EPS is a positive indicator for investors, suggesting better-than-expected profitability. However, the miss on sales and the YoY decline may raise concerns about revenue growth. Overall, the strong EPS beat is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100